<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110187</url>
  </required_header>
  <id_info>
    <org_study_id>JPS-001</org_study_id>
    <nct_id>NCT01110187</nct_id>
  </id_info>
  <brief_title>A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide</brief_title>
  <official_title>A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial to determine if seizure prophylaxis with IV LCM in NSICU patients experiencing mental
      status changes due to severe traumatic brain injury (sTBI) will result in improved short- and
      long-term outcomes and better immediate adverse effects when compared to the current standard
      of care anticonvulsant (IV fPHT) and will be at least as effective as IV fPHT in preventing
      clinical and sub-clinical seizure activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goals are to compare IV LCM and IV fPHT for seizure prophylaxis in the neuro-critical
      care setting in terms of the following outcome measures:

        1. The short- and long-term incidence of adverse events related to the anticonvulsant
           medication

        2. The frequency of clinically-evident and sub-clinical seizures, as demonstrated by
           continuous EEG monitoring for the first three days and by clinical assessment for up to
           6 months after initial admission.

        3. Intermediate and long-term outcomes as measured by standard outcome measures including
           Extended Glasgow Outcome Scale, Disability Rating Scale, and Resource Utilization
           Questionnaire
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of enrollement
  </why_stopped>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>baseline to 7 days</time_frame>
    <description>The primary outcome measure is the incidence of clinical adverse events. These will be followed by daily clinical observations during the hospital stay. Subjects will be evaluated for e.g., seizures, fever, neurological changes, cardiovascular, hematologic and dermatologic abnormalities, liver failure, renal failure, and death; EKGs will be requested as per ICU routines through day 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Seizures</measure>
    <time_frame>baseline to 72 hours</time_frame>
    <description>Number of seizures in the first 72 hours based on EEG recording</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>IV LCM (lacosamide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with severe traumatic brain injury (TBI) or subarachanoid hemorrhage (SAH) randomized to seizure prophylaxis with either lacosamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV fPHT (fos-phenytoin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with TBI or SAH randomized to seizure prophylaxis with fos-phenytoin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lacosamide</intervention_name>
    <description>200 mg IV over 60 minutes; these patients will then be started on a maintenance dose 100 mg, IV BID as prophylaxis administered as per pharmacy protocol consistent with acceptable standards of care for 7 days. The Lacosamide dose can be adjusted as needed if seizures occur for therapeutic effect up to 200 mg bid (400 mg/d) as a maximum dose.</description>
    <arm_group_label>IV LCM (lacosamide)</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosphenytoin</intervention_name>
    <description>20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days</description>
    <arm_group_label>IV fPHT (fos-phenytoin)</arm_group_label>
    <other_name>Dilantin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with traumatic brain injury admitted to the hospital less than 24 hours prior
             to randomization

          -  GCS score 3-8 (inclusive) or GCS motor score of 5 or less and abnormal admission CT
             scan showing intracranial pathology

          -  Hemodynamically stable with a systolic BP &gt; 90 mmHg

          -  At least one reactive pupil

          -  Age at least 18 years

          -  Signed informed consent and HIPAA authorization for research form

          -  Patients will not be excluded because of race, gender, educational status or
             occupation

        Exclusion Criteria:

          -  No venous access

          -  Spinal cord injury

          -  History of or CT confirmation of previous brain injury such as brain tumor, cerebral
             infarct, or spontaneous intracerebral hemorrhage

          -  Hemodynamically unstable

          -  Suspected anoxic events

          -  Other peripheral trauma likely to result in liver failure

          -  Age less than 18 years of age

          -  Known hypersensitivity to any anticonvulsant

          -  Any treatment, condition, or injury that contraindicates treatment with Lacosamide
             (LCM) or fos-phenytoin (fPHT)

          -  Inability to obtain signed informed consent or HIPAA authorization for research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerzy P Szaflarski, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Health University Pointe</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Health Medical Arts Building</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010 Apr;12(2):165-72. doi: 10.1007/s12028-009-9304-y.</citation>
    <PMID>19898966</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2010</study_first_posted>
  <results_first_submitted>June 19, 2013</results_first_submitted>
  <results_first_submitted_qc>March 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 28, 2014</results_first_posted>
  <last_update_submitted>March 26, 2014</last_update_submitted>
  <last_update_submitted_qc>March 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jerzy P Szaflarski</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Lacosamide</keyword>
  <keyword>Fosphenytoin</keyword>
  <keyword>traumatic brain injury</keyword>
  <keyword>Glasgow coma scale</keyword>
  <keyword>Disability Rating Scale</keyword>
  <keyword>Resource Utilization Questionnaire</keyword>
  <keyword>Continuous EEG</keyword>
  <keyword>seizures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
    <mesh_term>Fosphenytoin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IV LCM</title>
          <description>Patients with severe TBI later randomized to seizure prophylaxis with LCM (Lacosamide). For IV LCM dosing and adjustment see &quot;Intervention&quot; section.</description>
        </group>
        <group group_id="P2">
          <title>IV fPHT</title>
          <description>Patients randomized to fPHT (fos-phenytoin) with moderate or severe TBI. For IV fPHT dosing and adjustment see &quot;Intervention&quot; section.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7">completed 7 day treatment</participants>
                <participants group_id="P2" count="4">completed 7 day treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Traumatic Brain Injury</population>
      <group_list>
        <group group_id="B1">
          <title>IV LCM</title>
          <description>patients randomized to IV LCM (7)</description>
        </group>
        <group group_id="B2">
          <title>IV fPHT</title>
          <description>patients randomized to IV fPHT (4)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="38" upper_limit="66"/>
                    <measurement group_id="B2" value="55.5" lower_limit="23" upper_limit="61"/>
                    <measurement group_id="B3" value="56" lower_limit="23" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events</title>
        <description>The primary outcome measure is the incidence of clinical adverse events. These will be followed by daily clinical observations during the hospital stay. Subjects will be evaluated for e.g., seizures, fever, neurological changes, cardiovascular, hematologic and dermatologic abnormalities, liver failure, renal failure, and death; EKGs will be requested as per ICU routines through day 7.</description>
        <time_frame>baseline to 7 days</time_frame>
        <population>all participants in each arm were available for analyses</population>
        <group_list>
          <group group_id="O1">
            <title>IV LCM</title>
            <description>Patients with severe TBI later randomized to seizure prophylaxis with lacosamide.</description>
          </group>
          <group group_id="O2">
            <title>IV fPHT</title>
            <description>Patients with severe TBI randomized to seizure prophylaxis with fPHT</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events</title>
          <description>The primary outcome measure is the incidence of clinical adverse events. These will be followed by daily clinical observations during the hospital stay. Subjects will be evaluated for e.g., seizures, fever, neurological changes, cardiovascular, hematologic and dermatologic abnormalities, liver failure, renal failure, and death; EKGs will be requested as per ICU routines through day 7.</description>
          <population>all participants in each arm were available for analyses</population>
          <units>number of events experienced</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Seizures</title>
        <description>Number of seizures in the first 72 hours based on EEG recording</description>
        <time_frame>baseline to 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV LCM</title>
            <description>Patients with severe traumatic brain injury (TBI) or subarachanoid hemorrhage (SAH) randomized to seizure prophylaxis with either lacosamide.
lacosamide: 200 mg IV over 60 minutes; these patients will then be started on a maintenance dose 100 mg, IV BID as prophylaxis administered as per pharmacy protocol consistent with acceptable standards of care for 7 days. The Lacosamide dose can be adjusted as needed if seizures occur for therapeutic effect up to 200 mg bid (400 mg/d) as a maximum dose.</description>
          </group>
          <group group_id="O2">
            <title>IV fPHT</title>
            <description>Patients with TBI or SAH randomized to seizure prophylaxis with fos-phenytoin
Fosphenytoin: 20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seizures</title>
          <description>Number of seizures in the first 72 hours based on EEG recording</description>
          <units>number of participants with seizures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>baseline to 7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IV LCM</title>
          <description>Patients with severe TBI later randomized to seizure prophylaxis with lacosamide.</description>
        </group>
        <group group_id="E2">
          <title>IV fPHT</title>
          <description>Patients with severe TBI later randomized to seizure prophylaxis with phenytoin.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>death because of baseline condition (TBI) - expected</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>low platelets</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>arrythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>LFT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>increased ICP</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to lack of enrollment. Statistical comparisons between groups are not possible and were not performed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jerzy P. Szaflarski, MD</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-934-3866</phone>
      <email>szaflaj@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

